AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

In the claims

Claim 1-33 (Canceled)

Claim 34 (Currently amended): A composition comprising:

an effective amount of a biologically active agent;

a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and

a pharmaceutically acceptable carrier;

wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex~~. The composition of claim 33,~~ , and wherein the biologically active agent is an antiviral agent selected from the group consisting of acyclovir, famciclovir, ganciclovir, foscarnet, idoxuridine, sorivudine, trifluridine, valacyclovir, cidofovir, didanosine, stavudine, zalcitabine, zidovudine, ribavirin and rimantatine.

Claim 35 (Currently amended): A composition comprising:

an effective amount of a biologically active agent;

a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and

a pharmaceutically acceptable carrier;

wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex~~. The composition of claim 32,~~ , and wherein the biologically active agent is an antibacterial agent selected from the group consisting of nafcillin, oxacillin, penicillin,

amoxacillin, ampicillin, cefotaxime, ceftriaxone, rifampin, minocycline, ciprofloxacin, norfloxacin, erythromycin and vancomycin.

Claim 36 (Currently amended): A composition comprising:

an effective amount of a biologically active agent;

a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and

a pharmaceutically acceptable carrier;

wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex. ~~The composition of claim 32,~~ , and wherein the biologically active agent is an antifungal agent selected from the group consisting of amphotericin, itraconazole, ketoconazole, miconazole, nystatin, clotrimazole, fluconazole, ciclopirox, econazole, naftifine, terbinafine and griseofulvin.

Claim 37 (Currently amended): A composition comprising:

an effective amount of a biologically active agent;

a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and

a pharmaceutically acceptable carrier;

wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex. ~~The composition of claim 32,~~ , and wherein the biologically active agent is an antineoplastic agent selected from the group consisting of pentostatin, 6-mercaptopurine, 6-thioguanine, methotrexate, bleomycins, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, mitoxantrone, hydroxyurea, 5-fluorouracil, cytarabine, fludarabine, mitomycin, cisplatin, procarbazine, dacarbazine, paclitaxel, colchicine, and the vinca alkaloids.

Claim 38 (Currently amended): A composition comprising:

an effective amount of a biologically active agent;

a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and

a pharmaceutically acceptable carrier;

wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex. ~~The composition of claim 32,~~ , and wherein the biologically active agent is an immunosuppressive agent selected from the group consisting of methotrexate, azathioprine, fluorouracil, hydroxyurea, b-thioguanine, chclophosphamide, mechloroethamine hydrochloride, carmustine, cyclosporine, taxol or a phosphate-cleavable taxol conjugate, tacrolimus, vinblastine, dapsone and sulfasalazine.

Claim 39 (Currently amended): A composition comprising:

an effective amount of a biologically active agent;

a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and

a pharmaceutically acceptable carrier;

wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex. ~~The composition of claim 32,~~ , and wherein the biologically active agent is an analgesic agent selected from the group consisting of lidocaine, bupivacaine, novocaine, procaine, tetracaine, benzocaine, cocaine, mepivacaine, etidocaine, proparacaine ropivacaine and prilocaine.

Claim 40 (Canceled)